Linnman, NilsCatana, CiprianPetkov, Mike P.Chonde, Daniel BurjeBecerra, LinoHooker, JacobBorsook, David2018-01-182017Linnman, Clas, Ciprian Catana, Mike P. Petkov, Daniel Burje Chonde, Lino Becerra, Jacob Hooker, and David Borsook. 2017. “Molecular and functional PET-fMRI measures of placebo analgesia in episodic migraine: Preliminary findings.” NeuroImage : Clinical 17 (1): 680-690. doi:10.1016/j.nicl.2017.11.011. http://dx.doi.org/10.1016/j.nicl.2017.11.011.http://nrs.harvard.edu/urn-3:HUL.InstRepos:34651913Pain interventions with no active ingredient, placebo, are sometimes effective in treating chronic pain conditions. Prior studies on the neurobiological underpinnings of placebo analgesia indicate endogenous opioid release and changes in brain responses and functional connectivity during pain anticipation and pain experience in healthy subjects. Here, we investigated placebo analgesia in healthy subjects and in interictal migraine patients (n = 9) and matched healthy controls (n = 9) using 11C-diprenoprhine Positron Emission Tomography (PET) and simultaneous functional Magnetic Resonance Imaging (fMRI). Intravenous saline injections (the placebo) led to lower pain ratings, but we did not find evidence for an altered placebo response in interictal migraine subjects as compared to healthy subjects.en-USJournal Article2018-01-1810.1016/j.nicl.2017.11.011